Velox Genetics Inc.

Genetic Testing Transformed by Game Changing Technology


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Velox Genetics makes genetic testing run at lightning speed.

Normally it takes up to 30 mins to finish a MiRNA test but our revolutionary software accelerates the process by a factor of 30, completing the test in just 45 seconds.

That’s whole genome sequencing (WGS), processed in one hour.

For newborns, every minute counts, and being able to diagnose an illness as a genetic disorder could be the difference between life and death – a difference that the speed of our genetic testing software can make.

Velox Genetics is so incredibly fast, affordable and effective that genetic testing will become as common as a blood test.

Since the first sequencing of the entire human genome in 2000, genetic testing has come a long way. Both costs and the time it takes to complete testing have been reduced considerably. In 2010, researchers from the Medical College of Wisconsin managed for the first time to successfully change the treatment of a patient based on WGS.

Advances in genetic testing are important, because more and more diseases are proving linked to genetics. This might sound frightening, but the correlation bodes well for treatment. The sooner doctors can confirm their suspicions that an illness is genetic, the faster they can begin proper treatment. If people know their WGS early on, they can address genetic deficiencies that may otherwise take time to manifest, or they can take proper preventative measures.

Wikipedia

Efficient genetic testing has implications for the treatment of many illnesses:

So, if genetic testing is such a potent tool, why isn’t everyone already having it done?

The simple answer is that it takes too long, costs too much, and relies on technology not widely available.

Typically, there are three phases to genetic testing.

The test results can take as long as 24 hours to complete, and another longer period to analyze. Cross referencing the huge amounts of raw data to the reference database has in the past required hardware designed specifically for genomic data analysis as well as specialized software in order to be conducted accurately. This technology has been a major reason why tests have cost thousands of dollars.

There is a race to sequence a human genome for under $1,000. Velox’s software solution requires no special hardware and is 30 times faster at cross referencing the raw data to the reference database than current solutions.

Obtaining the raw sample hasn’t been an issue. This means that unlocking the medical potential of genetic testing has only been a matter of developing capable technology (cheap enough for common use).

That’s where Velox Genetics comes in.

Using proprietary technology, we can realize full genome testing results in one hour. How is this possible? Purely computational, my dear Watson. Applying theories from telecom, we sped up the process of matching raw data to the reference database. We built the data processing software from scratch so  we can apply a logic unlike any other used in genetic testing.

At last, genetic testing will become a regular part of anyone’s healthcare regimen. It will be possible to detect genetic diseases early on and for those with them to gain early understanding of their conditions. Those who are predisposed to diseases will understand their likelihood of having them and can take preemptive action. Everyone benefits –

 

Patients
For the first time, patients will have widespread access to WGS.

 

 

Physicians
Physicians will now have vital patient information that will enable them to treat patients more effectively.

 

 

Healthcare and insurance companies
Providing quick tests is cost effective. Healthcare and insurance companies can distinguish themselves as service providers by offering genetic tests.

 

 

Pharmaceuticals
Collecting WGS data has the potential to lead to breakthroughs in drug responsiveness.

 

Money saved. Knowledge gained. Healthcare transformed.

By accelerating genetic testing, Velox will change the world

The core of our technology has been in use for over ten years, and we’re prepared to transform the genetic testing industry with our unrivaled speed.

With this kind of speed, it won’t be long before Velox Genetics will be the bright star of the genetic testing industry. We already have 2 major biotechs interested in buying our software.

We’ve done the hard work of making WGS practical, and now it’s time to make the life-altering benefits of genetic testing available to the world.

Ready to hear more about the Velox Genetics opportunity? Request access to the Business Plan tab of this profile, and let’s talk!

Often it takes the perspective of someone who hasn’t been looking directly at a problem to see the solution. When it came to speeding the processing time from raw data samples to results, the technology involved in genetic testing had reached it’s limit. Fortunately, just down the street from Edico Genome, a company working on the time issue, is an accomplished entrepreneur who recognized that he could apply the knowledge and technology from the telecom industry to genetic testing.

Joseph Putegnat - Founder
Joseph has been an entrepreneur in the telecom space for over 25 years. As the Founder and CEO, he built three public telecom companies from scratch.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.